申请人:Bayer Corporation
公开号:US06218431B1
公开(公告)日:2001-04-17
Substituted biphenyls having glucagon receptor antagonistic activity. Claimed compounds have the formula
wherein
R1a and R1b independently represent (C1-C6) alkyl; R2 represents (C1-C10) alkyl or substituted (C1-C10) alkyl wherein the substituents are independently from 1 to 3 of —SR7; R7 represents phenyl, or substituted phenyl wherein the substituents are independently 1-5 of halogen, trifluoromethyl, (C1-C6) alkyl, (C1-C6) alkoxy, nitro, cyano, or hydroxyl; R3 represents substituted (C1-C6) alkyl wherein the substituents are 1-2 hydroxyl groups; G represents a substituent selected from the group consisting of halogen, (C1-C6) alkyl, and OR4 wherein R4 is H or (C1-C6) alkyl; and y is 0 or an integer of 1-3. Pharmaceutical compositions containing such compounds and methods of treatment of glucagon-mediated conditions by administering such compounds are also claimed.
具有葡萄糖高原素受体拮抗活性的取代联苯。所述化合物的公式为其中R1a和R1b独立地表示(C1-C6)烷基;R2表示(C1-C10)烷基或取代的(C1-C10)烷基,其中取代基独立地为1-3个- SR7; R7表示苯基或取代的苯基,其中取代基独立地为1-5个卤素,三氟甲基,(C1-C6)烷基,(C1-C6)烷氧基,硝基,氰基或羟基;R3表示取代的(C1-C6)烷基,其中取代基为1-2个羟基;G表示从卤素,(C1-C6)烷基和OR4中选择的取代基,其中R4为H或(C1-C6)烷基;y为0或1-3的整数。还声明了包含这些化合物的药物组合物以及通过给予这些化合物进行治疗葡萄糖高原素介导的疾病的方法。